The self-referred serosurvey data showed that the whole of India, 31% population has SARS-CoV-2 antibodies. Seroprevalence was higher in females (35%) than males (30%). The seropositivity in Ahmedabad, Jaipur, Bangalore, and Delhi increased monotonously from July to December. Seropositivity in big cities of India was as high as 63.8% in Bangalore followed by Delhi (54.9%) and Kolkata (54.6%). In cities (Mumbai, Chennai, Pune, Coimbatore, Surat, Visakhapatnam, Kolkata, and Nagpur) antibodies prevalence first increased with time after a threshold it started decreasing in 4 month time in most of the cities. Intergeneration age dependent seropositivity for both males and females showed an “M-shaped” pattern. The seroprevalence versus monthly infection rate in Delhi and Kolkata showed an increase in seroprevalence with the caseload. In Chennai, the caseload of new infections decreased while seropositivity increased. In the case of Mumbai, seropositivity increased with increase in the caseload in the beginning till October, after that with decrease in the caseload seroprevalence also diminished. In none of the cities, the amount of antibodies titers was enough to stop the second wave of the pandemic.
Delta variant is taking hold of Europe: WHO, The Hindu, June 10, 2021.
Japan widens virus emergency to three more prefectures, Reuters, May 14, 2021.
Fear of ‘4th wave’ rise with surging rural Japan coronavirus infections, The Mainichi, March 26, 2021.
Japan daily COVID-19 cases below 1,000 for the first time since March, The Japan Times, June 14, 2021.
Only 3.5% of the population is fully vaccinated as of June 13, 2021, The Hindu, June 13, 2021.
Covid second wave: 3.8mn new cases, 61K deaths in 4 months in Maharashtra, Hindustan Times, June 15, 2021.
Shervani et al. Dharavi Slums (Mumbai, India): The Petri Dish of COVID-19 Herd Immunity, European Journal of Medical and Health Sciences, 3, 2021, 38-41.
Shervani Z, “COVID-19 in Kerala: Health Index Theory,” European Journal of Medical and Health Sciences, 3, 2021, 21-24.
Shervani Z, “COVID-19 in Kerala: The Dynamics of Spread and Health Index Theory,” RAS Medical Science, 2021, 1, 1-3.
Shervani Z, et al. “Viability of SARS-CoV-2 and Sanitization Methods,” European Journal of Medical and Health Sciences, 3(2021)22-27.
Shervani Z, et al. “Risk of SARS-CoV-2 Transmission from Humans to Pets and Vice Versa,” European Journal of Medical and Health Sciences, 3(2021)34-38.
Shervani Z, et al. “SARS-CoV-2 Delayed Tokyo 2020 Olympics: Very Recent Advances in COVID-19 Detection, Treatment, and Vaccine Development Useful Conducting the Games in 2021,” Advances in Infectious Diseases, 2020; 10: 56-66.
Shervani Z, et al., “COVID-19 Vaccine,” Advances in Infectious Diseases, 2020;10: 195-210.
Shervani Z, et al., “World’s Fastest Supercomputer Picks COVID-19 Drug,” Advances in Infectious Diseases, 2020; 10: 211-225.
Velumani A., et al. SARS-CoV-2 Seroprevalence in 12 Cities of India from July-December 2020,
Covid-19 antibodies diminish over time, but experts say there's no reason to be alarmed, NBC NEWS.COM, October 31, 2020.